AYTU logo

AYTU
Aytu BioPharma Inc

40,553
Mkt Cap
$23.51M
Volume
75,972.00
52W High
$3.07
52W Low
$1.46
PE Ratio
-0.48
AYTU Fundamentals
Price
$2.19
Prev Close
$2.27
Open
$2.27
50D MA
$2.56
Beta
0.80
Avg. Volume
31,050.65
EPS (Annual)
-$2.16
P/B
0.67
Rev/Employee
$799,783.13
$5.67
Loading...
Loading...
News
all
press releases
Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates
Aytu BioPharma, Inc. (AYTU) delivered earnings and revenue surprises of -70.97% and +3.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
More News
News Placeholder
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics (IMTX) delivered earnings and revenue surprises of -19.05% and -38.95%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
Puma Biotech (PBYI) Reports Q1 Loss, Tops Revenue Estimates
Puma Biotech (PBYI) delivered earnings and revenue surprises of +68.00% and +14.23%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·9d ago
News Placeholder
Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates
Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -303.85% and +26.27%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
Aytu BioPharma AYTU Q2 2026 Earnings Transcript
@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...
Nasdaq News: Markets·3mo ago
News Placeholder
New Strong Sell Stocks for February 2nd
AAWH, AYTU and BCAL have been added to the Zacks Rank #5 (Strong Sell) List on February 2, 2026.
Zacks·3mo ago
News Placeholder
Aytu BioPharma Inc. (AYTU) Reports Q1 Loss, Tops Revenue Estimates
Aytu BioPharma (AYTU) delivered earnings and revenue surprises of -33.33% and +10.05%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Insights into Aytu BioPharma's Upcoming Earnings
read more...
Benzinga·6mo ago
News Placeholder
Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates
Astria Therapeutics (ATXS) delivered earnings and revenue surprises of -34.15% and -95.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
News Placeholder
Eton Pharmaceuticals, Inc. (ETON) Reports Q3 Loss, Beats Revenue Estimates
Eton Pharmaceuticals (ETON) delivered earnings and revenue surprises of -153.85% and +9.24%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6mo ago
<
1
2
...
>

Latest AYTU News

View
Top Discussions